Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that 17p deletion status confers therapeutic sensitivity to Ibrutinib in patients with Chronic Lymphocytic Leukemia.
This statement is based on a regulatory approval from the Health Service Executive:
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.